DRUG THERAPY AND PREGNANCY: UNKNOWN RISKS LEAD TO HARD CHOICES [REDACTED VERSION]

DSpace/Manakin Repository

DRUG THERAPY AND PREGNANCY: UNKNOWN RISKS LEAD TO HARD CHOICES [REDACTED VERSION]

Show simple item record

dc.contributor.advisor Hutt, Peter Barton en_US
dc.contributor.author Goldstein, Lori M. en_US
dc.date.accessioned 2012-07-06T21:39:31Z
dc.date.issued 2001 en_US
dc.identifier.citation DRUG THERAPY AND PREGNANCY: UNKNOWN RISKS LEAD TO HARD CHOICES [REDACTED VERSION] (2001 Third Year Paper) en
dc.identifier.uri http://nrs.harvard.edu/urn-3:HUL.InstRepos:8965596
dc.description.abstract This paper is a proposal to improve the quality of information available to pregnant patients in selecting treatment options. By providing drug companies with extended grants of exclusivity, the FDA has the ability to empower pregnant women to take control of their health and make informed decisions. Granted post-marketing surveillance will always catch ADRs at a later stage of the game than pre-market clinical trials, but in the case of pregnant women; where we must concern ourselves with potential harms to a future sentient child - increased rigor in the method and quantity of post marketing surveillance techniques seems like the only way to go. en
dc.language.iso en_US en
dash.license LAA en_US
dc.subject Food and Drug Law en
dc.subject FDA en
dc.subject pregnancy en
dc.subject drug testing en
dc.title DRUG THERAPY AND PREGNANCY: UNKNOWN RISKS LEAD TO HARD CHOICES [REDACTED VERSION] en
dc.type Paper (for course/seminar/workshop) en_US
dc.date.available 2012-07-06T21:39:31Z

Files in this item

Files Size Format View
Goldstein.pdf 141.0Kb PDF View/Open
Goldstein.rtf 52.76Kb RTF file View/Open
Goldstein.html 49.84Kb HTML View/Open

This item appears in the following Collection(s)

Show simple item record

 
 

Search DASH


Advanced Search
 
 

Submitters